Immunotherapy Targeting Misfolded Proteins in Neurodegenerative Disease Kazutomi Kanemaru 1 1Department of Neurology, Tokyo Metropolitan Geriatric Hospital Keyword: neurodegenerative disease , misfolded protein , seeded aggregation , immunotherapy , antibody pp.469-474
Published Date 2013/4/1
DOI https://doi.org/10.11477/mf.1416101477
  • Abstract
  • Look Inside
  • Reference


 Aberrant protein aggregation is closely linked to the molecular pathogeneses of most neurodegenerative diseases. The major components of pathological aggregates have been characterized in various neurodegenerative diseases; for example, amyloid β-protein and phosphorylated tau in Alzheimer's disease, α-synuclein in Parkinson's disease, SOD1 or TDP-43 in amyotrophic lateral sclerosis, and huntingtin in Huntington's disease. These misfolded protein aggregates play a vital role in disease initiation and progression, and they have recently been shown to have prion-like spreading or seeded aggregation properties. Immunotherapy with specific monoclonal antibodies is a promising approach to clear misfolded protein aggregates and treat various neurodegenerative diseases; it is planned for use in clinical trials in the near future.

Copyright © 2013, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院